Published in Infect Immun on December 01, 2005
Beyond natural antibodies: the power of in vitro display technologies. Nat Biotechnol (2011) 2.41
A requirement for FcγR in antibody-mediated bacterial toxin neutralization. J Exp Med (2010) 1.58
Characterization of a novel high-affinity monoclonal immunoglobulin G antibody against the ricin B subunit. Infect Immun (2006) 1.50
Detection of anthrax toxin in the serum of animals infected with Bacillus anthracis by using engineered immunoassays. Clin Vaccine Immunol (2006) 1.50
In vitro and in vivo characterization of anthrax anti-protective antigen and anti-lethal factor monoclonal antibodies after passive transfer in a mouse lethal toxin challenge model to define correlates of immunity. Infect Immun (2007) 1.33
Neutralising antibodies against ricin toxin. PLoS One (2011) 1.26
Detection of anthrax toxin by an ultrasensitive immunoassay using europium nanoparticles. Clin Vaccine Immunol (2009) 1.15
Anti-toxin antibodies in prophylaxis and treatment of inhalation anthrax. Future Microbiol (2009) 1.11
A three-dose intramuscular injection schedule of anthrax vaccine adsorbed generates sustained humoral and cellular immune responses to protective antigen and provides long-term protection against inhalation anthrax in rhesus macaques. Clin Vaccine Immunol (2012) 1.10
Lethal and edema toxins in the pathogenesis of Bacillus anthracis septic shock: implications for therapy. Am J Respir Crit Care Med (2006) 1.08
Anthrax vaccination strategies. Mol Aspects Med (2009) 1.08
An engineered human antibody fab fragment specific for Pseudomonas aeruginosa PcrV antigen has potent antibacterial activity. Infect Immun (2008) 1.03
Crystal structure of the engineered neutralizing antibody M18 complexed to domain 4 of the anthrax protective antigen. J Mol Biol (2009) 1.01
Targeting pili in enterococcal pathogenesis. Infect Immun (2014) 0.97
Nano aptasensor for protective antigen toxin of anthrax. Anal Chem (2010) 0.95
Humanization and characterization of an anti-ricin neutralization monoclonal antibody. PLoS One (2012) 0.94
Neutralizing activity and protective immunity to ricin toxin conferred by B subunit (RTB)-specific Fab fragments. Toxicon (2013) 0.86
APEx 2-hybrid, a quantitative protein-protein interaction assay for antibody discovery and engineering. Proc Natl Acad Sci U S A (2007) 0.86
Anamnestic protective immunity to Bacillus anthracis is antibody mediated but independent of complement and Fc receptors. Infect Immun (2008) 0.85
Genetic medicine strategies to protect against bioterrorism. Trans Am Clin Climatol Assoc (2006) 0.83
Conformation-dependent high-affinity potent ricin-neutralizing monoclonal antibodies. Biomed Res Int (2012) 0.82
The International Bacillus anthracis, B. cereus, and B. thuringiensis Conference, "Bacillus-ACT05". J Bacteriol (2006) 0.81
Affinity maturation of an anti-V antigen IgG expressed in situ through adenovirus gene delivery confers enhanced protection against Yersinia pestis challenge. Gene Ther (2010) 0.80
Rapid generation of an anthrax immunotherapeutic from goats using a novel non-toxic muramyl dipeptide adjuvant. J Immune Based Ther Vaccines (2007) 0.79
Epitope characterization of sero-specific monoclonal antibody to Clostridium botulinum neurotoxin type A. Hybridoma (Larchmt) (2011) 0.77
Preparation and evaluation of human-murine chimeric antibody against protective antigen of Bacillus anthracis. Int J Mol Sci (2014) 0.77
Charge Variants of an Avastin Biosimilar Isolation, Characterization, In Vitro Properties and Pharmacokinetics in Rat. PLoS One (2016) 0.75
A single mouse monoclonal antibody, E58 modulates multiple IgE epitopes on group 1 cedar pollen allergens. Mol Immunol (2016) 0.75
Identification of the cellular receptor for anthrax toxin. Nature (2001) 8.78
Demonstration of a capsule plasmid in Bacillus anthracis. Infect Immun (1985) 8.46
Human capillary morphogenesis protein 2 functions as an anthrax toxin receptor. Proc Natl Acad Sci U S A (2003) 5.95
Anthrax toxin. Annu Rev Cell Dev Biol (2003) 5.92
BIOCHEMISTRY OF SPORULATION. II. ENZYMATIC CHANGES DURING SPORULATION OF BACILLUS CEREUS. J Bacteriol (1963) 3.93
Crystal structure of the anthrax lethal factor. Nature (2001) 3.75
Structural basis for the activation of anthrax adenylyl cyclase exotoxin by calmodulin. Nature (2002) 3.67
Crystal structure of a complex between anthrax toxin and its host cell receptor. Nature (2004) 3.36
Structure of heptameric protective antigen bound to an anthrax toxin receptor: a role for receptor in pH-dependent pore formation. Proc Natl Acad Sci U S A (2004) 3.10
Dominant-negative mutants of a toxin subunit: an approach to therapy of anthrax. Science (2001) 2.84
Protection against anthrax toxin by recombinant antibody fragments correlates with antigen affinity. Nat Biotechnol (2002) 2.77
Cell surface tumor endothelium marker 8 cytoplasmic tail-independent anthrax toxin binding, proteolytic processing, oligomer formation, and internalization. J Biol Chem (2002) 2.76
Comparative efficacy of experimental anthrax vaccine candidates against inhalation anthrax in rhesus macaques. Vaccine (1998) 2.74
Designing a polyvalent inhibitor of anthrax toxin. Nat Biotechnol (2001) 2.67
Production and characterization of monoclonal antibodies to the protective antigen component of Bacillus anthracis toxin. Infect Immun (1988) 2.63
Binding stoichiometry and kinetics of the interaction of a human anthrax toxin receptor, CMG2, with protective antigen. J Biol Chem (2004) 2.57
The role of antibodies to Bacillus anthracis and anthrax toxin components in inhibiting the early stages of infection by anthrax spores. Microbiology (2001) 2.55
Passive protection by polyclonal antibodies against Bacillus anthracis infection in guinea pigs. Infect Immun (1997) 2.53
Reliable cloning of functional antibody variable domains from hybridomas and spleen cell repertoires employing a reengineered phage display system. J Immunol Methods (1997) 2.44
Isolation of high-affinity ligand-binding proteins by periplasmic expression with cytometric screening (PECS). Nat Biotechnol (2001) 2.00
Mutations in the gene encoding capillary morphogenesis protein 2 cause juvenile hyaline fibromatosis and infantile systemic hyalinosis. Am J Hum Genet (2003) 1.94
Identification of small molecule inhibitors of anthrax lethal factor. Nat Struct Mol Biol (2003) 1.86
Anthrax lethal factor inhibition. Proc Natl Acad Sci U S A (2005) 1.83
Quantitative analysis of the effect of the mutation frequency on the affinity maturation of single chain Fv antibodies. Proc Natl Acad Sci U S A (2000) 1.80
Antitoxins: novel strategies to target agents of bioterrorism. Nat Rev Microbiol (2004) 1.67
Internalization of a Bacillus anthracis protective antigen-c-Myc fusion protein mediated by cell surface anti-c-Myc antibodies. Mol Med (1998) 1.64
ATR/TEM8 is highly expressed in epithelial cells lining Bacillus anthracis' three sites of entry: implications for the pathogenesis of anthrax infection. Am J Physiol Cell Physiol (2005) 1.61
A high-affinity monoclonal antibody to anthrax protective antigen passively protects rabbits before and after aerosolized Bacillus anthracis spore challenge. Infect Immun (2005) 1.61
Selection of Bacillus anthracis isolates resistant to antibiotics. J Antimicrob Chemother (2004) 1.60
In-vitro characterisation of the phagocytosis and fate of anthrax spores in macrophages and the effects of anti-PA antibody. J Med Microbiol (2002) 1.60
Antibody therapy in the management of shiga toxin-induced hemolytic uremic syndrome. Clin Microbiol Rev (2004) 1.55
Anchored periplasmic expression, a versatile technology for the isolation of high-affinity antibodies from Escherichia coli-expressed libraries. Proc Natl Acad Sci U S A (2004) 1.54
Isolation and expression of recombinant antibody fragments to the biological warfare pathogen Brucella melitensis. J Immunol Methods (2003) 1.44
Human alpha-defensins neutralize anthrax lethal toxin and protect against its fatal consequences. Proc Natl Acad Sci U S A (2005) 1.38
Postexposure prophylaxis against anthrax: evaluation of various treatment regimens in intranasally infected guinea pigs. Infect Immun (2002) 1.31
Escherichia coli skp chaperone coexpression improves solubility and phage display of single-chain antibody fragments. Protein Expr Purif (1999) 1.22
A dominant negative mutant of Bacillus anthracis protective antigen inhibits anthrax toxin action in vivo. J Biol Chem (2001) 1.16
Fc gamma receptors. Immunol Lett (2004) 1.09
Preclinical manufacture of anti-HER2 liposome-inserting, scFv-PEG-lipid conjugate. 2. Conjugate micelle identity, purity, stability, and potency analysis. Biotechnol Prog (2005) 1.06
Tailoring structure-function and pharmacokinetic properties of single-chain Fv proteins by site-specific PEGylation. Protein Eng (2003) 1.03
Production of soluble ScFvs with C-terminal-free thiol for site-specific conjugation or stable dimeric ScFvs on demand. Bioconjug Chem (2004) 1.03
Spontaneous assembly of bivalent single chain antibody fragments in Escherichia coli. Mol Immunol (1994) 1.00
Site-directed pegylation of recombinant interleukin-2 at its glycosylation site. Biotechnology (N Y) (1990) 1.00
Disruption of anthrax toxin binding with the use of human antibodies and competitive inhibitors. Infect Immun (1999) 0.94
Modulating pharmacokinetics of an anti-interleukin-8 F(ab')(2) by amine-specific PEGylation with preserved bioactivity. Int J Pharm (2000) 0.90
Polyethylene glycol modification of the monoclonal antibody A7 enhances its tumor localization. Biochem Biophys Res Commun (1990) 0.89
Suppression of reaginic antibodies with modified allergens. IV. Induction of suppressor T cells by conjugates of polyethylene glycol (PEG) and monomethoxy PEG with ovalbumin. Int Arch Allergy Appl Immunol (1981) 0.87
Characterization of site-specific ScFv PEGylation for tumor-targeting pharmaceuticals. Bioconjug Chem (2005) 0.85
Suppression of reaginic antibodies with modified allergens. II. Abrogation of reaginic antibodies with allergens conjugated to polyethylene glycol. Int Arch Allergy Appl Immunol (1978) 0.81
Site-directed polyethylene glycol modification of trichosanthin: effects on its biological activities, pharmacokinetics, and antigenicity. Life Sci (1999) 0.79
Pharmacodynamic enhancement of the anti-platelet antibody fab abciximab by site-specific pegylation. Platelets (2004) 0.77
Physicochemical and biological properties of poly(ethylene glycol)-coupled immunoglobulin G. Part II. Effect of molecular weight of poly(ethylene glycol). J Biomater Sci Polym Ed (1989) 0.77
Immunologic properties of conjugates of ragweed antigen E with various alkoxypolyethylene glycols. Int Arch Allergy Appl Immunol (1981) 0.76
Isolation of engineered, full-length antibodies from libraries expressed in Escherichia coli. Nat Biotechnol (2007) 3.56
Virus-based toolkit for the directed synthesis of magnetic and semiconducting nanowires. Science (2004) 3.08
High-throughput sequencing of the paired human immunoglobulin heavy and light chain repertoire. Nat Biotechnol (2013) 2.81
Protection against anthrax toxin by recombinant antibody fragments correlates with antigen affinity. Nat Biotechnol (2002) 2.77
Delayed occurrence of fatal neoplastic diseases in ames dwarf mice: correlation to extended longevity. J Gerontol A Biol Sci Med Sci (2003) 2.67
Display of heterologous proteins on the surface of microorganisms: from the screening of combinatorial libraries to live recombinant vaccines. Nat Biotechnol (1997) 2.54
Monoclonal antibodies isolated without screening by analyzing the variable-gene repertoire of plasma cells. Nat Biotechnol (2010) 2.41
Folding quality control in the export of proteins by the bacterial twin-arginine translocation pathway. Proc Natl Acad Sci U S A (2003) 2.26
The many faces of glutathione in bacteria. Antioxid Redox Signal (2006) 2.20
Mre11-Rad50-Xrs2 and Sae2 promote 5' strand resection of DNA double-strand breaks. Nat Struct Mol Biol (2010) 2.14
The bacterial twin-arginine translocation pathway. Annu Rev Microbiol (2006) 2.13
Function-based isolation of novel enzymes from a large library. Nat Biotechnol (2000) 2.12
Reduced incidence and delayed occurrence of fatal neoplastic diseases in growth hormone receptor/binding protein knockout mice. J Gerontol A Biol Sci Med Sci (2009) 2.08
Bacterial biosynthesis of cadmium sulfide nanocrystals. Chem Biol (2004) 2.02
Isolation of high-affinity ligand-binding proteins by periplasmic expression with cytometric screening (PECS). Nat Biotechnol (2001) 2.00
Viral assembly of oriented quantum dot nanowires. Proc Natl Acad Sci U S A (2003) 2.00
Housing density does not influence the longevity effect of calorie restriction. J Gerontol A Biol Sci Med Sci (2005) 1.85
Quantitative analysis of the effect of the mutation frequency on the affinity maturation of single chain Fv antibodies. Proc Natl Acad Sci U S A (2000) 1.80
Genetic analysis of the twin arginine translocator secretion pathway in bacteria. J Biol Chem (2002) 1.74
Spontaneous heart disease in the adult chimpanzee (Pan troglodytes). J Med Primatol (2008) 1.72
Virus nomenclature below the species level: a standardized nomenclature for natural variants of viruses assigned to the family Filoviridae. Arch Virol (2012) 1.59
Anchored periplasmic expression, a versatile technology for the isolation of high-affinity antibodies from Escherichia coli-expressed libraries. Proc Natl Acad Sci U S A (2004) 1.54
Production and fluorescence-activated cell sorting of Escherichia coli expressing a functional antibody fragment on the external surface. Proc Natl Acad Sci U S A (1993) 1.51
Detection of anthrax toxin in the serum of animals infected with Bacillus anthracis by using engineered immunoassays. Clin Vaccine Immunol (2006) 1.50
Identification and characterization of the constituent human serum antibodies elicited by vaccination. Proc Natl Acad Sci U S A (2014) 1.50
Engineering of protease variants exhibiting high catalytic activity and exquisite substrate selectivity. Proc Natl Acad Sci U S A (2005) 1.48
Why high-error-rate random mutagenesis libraries are enriched in functional and improved proteins. J Mol Biol (2005) 1.47
Effects of codon usage versus putative 5'-mRNA structure on the expression of Fusarium solani cutinase in the Escherichia coli cytoplasm. Protein Expr Purif (2003) 1.46
Modulating the innate immune response by combinatorial engineering of endotoxin. Proc Natl Acad Sci U S A (2013) 1.45
Functional, structural, and spectroscopic characterization of a glutathione-ligated [2Fe-2S] cluster in poplar glutaredoxin C1. Proc Natl Acad Sci U S A (2007) 1.45
Pancreatic islet amyloidosis, beta-cell apoptosis, and alpha-cell proliferation are determinants of islet remodeling in type-2 diabetic baboons. Proc Natl Acad Sci U S A (2009) 1.45
Isolation and expression of recombinant antibody fragments to the biological warfare pathogen Brucella melitensis. J Immunol Methods (2003) 1.44
A live attenuated vaccine for Lassa fever made by reassortment of Lassa and Mopeia viruses. J Virol (2005) 1.42
Production of correctly folded Fab antibody fragment in the cytoplasm of Escherichia coli trxB gor mutants via the coexpression of molecular chaperones. Protein Expr Purif (2001) 1.41
Lassa virus infection in experimentally infected marmosets: liver pathology and immunophenotypic alterations in target tissues. J Virol (2007) 1.41
Detecting lifetime alcohol problems in individuals referred for liver transplantation for nonalcoholic liver failure. Liver Transpl (2008) 1.40
Does reduced IGF-1R signaling in Igf1r+/- mice alter aging? PLoS One (2011) 1.39
High-resolution antibody dynamics of vaccine-induced immune responses. Proc Natl Acad Sci U S A (2014) 1.39
A systematic screen of FDA-approved drugs for inhibitors of biological threat agents. PLoS One (2013) 1.38
Human antibody against shiga toxin 2 administered to piglets after the onset of diarrhea due to Escherichia coli O157:H7 prevents fatal systemic complications. Infect Immun (2005) 1.38
Congenital midline cervical cleft: diagnosis, pathologic findings, and early stage treatment. Case Rep Pediatr (2012) 1.37
Strain engineering for improved expression of recombinant proteins in bacteria. Microb Cell Fact (2011) 1.36
RraA. a protein inhibitor of RNase E activity that globally modulates RNA abundance in E. coli. Cell (2003) 1.34
Phage shock protein PspA of Escherichia coli relieves saturation of protein export via the Tat pathway. J Bacteriol (2004) 1.34
Spontaneous neoplasia in the baboon (Papio spp.). J Med Primatol (2007) 1.34
Highly active and selective endopeptidases with programmed substrate specificities. Nat Chem Biol (2008) 1.33
An engineered pathway for the formation of protein disulfide bonds. Science (2004) 1.29
Automated selection of aptamers against protein targets translated in vitro: from gene to aptamer. Nucleic Acids Res (2002) 1.29
Export pathway selectivity of Escherichia coli twin arginine translocation signal peptides. J Biol Chem (2007) 1.28
Revisiting the role of glycosylation in the structure of human IgG Fc. ACS Chem Biol (2012) 1.28
Development of an optimized expression system for the screening of antibody libraries displayed on the Escherichia coli surface. Protein Eng (1999) 1.27
Discussions and decisions of the 2012–2014 International Committee on Taxonomy of Viruses (ICTV) Filoviridae Study Group, January 2012–June 2013. Arch Virol (2014) 1.27
Molecular deconvolution of the monoclonal antibodies that comprise the polyclonal serum response. Proc Natl Acad Sci U S A (2013) 1.26
Differential modulation of E. coli mRNA abundance by inhibitory proteins that alter the composition of the degradosome. Mol Microbiol (2006) 1.26
Productive replication of Ebola virus is regulated by the c-Abl1 tyrosine kinase. Sci Transl Med (2012) 1.24
Substrate specificity of the Escherichia coli outer membrane protease OmpT. J Bacteriol (2004) 1.23
Protection against lethal challenge by Ebola virus-like particles produced in insect cells. Virology (2008) 1.22
Functional plasticity of a peroxidase allows evolution of diverse disulfide-reducing pathways. Proc Natl Acad Sci U S A (2008) 1.22
Antibody remodeling: a general solution to the design of a metal-coordination site in an antibody binding pocket. Proc Natl Acad Sci U S A (1990) 1.20
Structure-based design of supercharged, highly thermoresistant antibodies. Chem Biol (2012) 1.19
Replacing Mn(2+) with Co(2+) in human arginase i enhances cytotoxicity toward l-arginine auxotrophic cancer cell lines. ACS Chem Biol (2010) 1.19
Recursive genomewide recombination and sequencing reveals a key refinement step in the evolution of a metabolic innovation in Escherichia coli. Proc Natl Acad Sci U S A (2013) 1.19
Therapeutic enzyme deimmunization by combinatorial T-cell epitope removal using neutral drift. Proc Natl Acad Sci U S A (2011) 1.18
Aglycosylated IgG variants expressed in bacteria that selectively bind FcgammaRI potentiate tumor cell killing by monocyte-dendritic cells. Proc Natl Acad Sci U S A (2009) 1.17
Virus nomenclature below the species level: a standardized nomenclature for laboratory animal-adapted strains and variants of viruses assigned to the family Filoviridae. Arch Virol (2013) 1.16
Synthetic antibody libraries focused towards peptide ligands. J Mol Biol (2008) 1.15
Non-human primate fetal kidney transcriptome analysis indicates mammalian target of rapamycin (mTOR) is a central nutrient-responsive pathway. J Physiol (2006) 1.15
A review of spontaneous neoplasia in baboons (Papio spp.). J Med Primatol (2005) 1.13
A ML29 reassortant virus protects guinea pigs against a distantly related Nigerian strain of Lassa virus and can provide sterilizing immunity. Vaccine (2007) 1.13
Antibody affinity maturation using bacterial surface display. Protein Eng (1998) 1.13
Filoviruses utilize glycosaminoglycans for their attachment to target cells. J Virol (2013) 1.11
Potential impact of a 2-person security rule on BioSafety Level 4 laboratory workers. Emerg Infect Dis (2009) 1.11
Effects of maternal global nutrient restriction on fetal baboon hepatic insulin-like growth factor system genes and gene products. Endocrinology (2009) 1.11
Cell-Surface display of heterologous proteins: From high-throughput screening to environmental applications. Biotechnol Bioeng (2002) 1.11
Virus nomenclature below the species level: a standardized nomenclature for filovirus strains and variants rescued from cDNA. Arch Virol (2013) 1.10
Common marmosets (Callithrix jacchus) as a nonhuman primate model to assess the virulence of eastern equine encephalitis virus strains. J Virol (2008) 1.10
Rapid construction and characterization of synthetic antibody libraries without DNA amplification. Biotechnol Bioeng (2010) 1.10
The human asparaginase-like protein 1 hASRGL1 is an Ntn hydrolase with beta-aspartyl peptidase activity. Biochemistry (2009) 1.10
Safety, immunogenicity, and efficacy of the ML29 reassortant vaccine for Lassa fever in small non-human primates. Vaccine (2008) 1.09
Antibody repertoires in humanized NOD-scid-IL2Rγ(null) mice and human B cells reveals human-like diversification and tolerance checkpoints in the mouse. PLoS One (2012) 1.09